Why the study?
Does infliximab therapy cause hemorrhagic pericardial effusion with tamponade?
Does infliximab therapy cause hemorrhagic pericardial effusion with tamponade?
Infliximab and other anti-TNF agents can rarely cause severe hemorrhagic pericarditis and tamponade, potentially linked to high anti-drug antibody titers.
May warrant vigilance for pericardial complications on anti-TNF therapy; leaves open the antibody-mediated mechanism pending confirmatory studies.
Introduction. Antitumor necrosis factor (TNF) alpha agents are commonly used biologic therapies for a wide variety of rheumatic and inflammatory diseases. Here, we present a case of hemorrhagic pericarditis as a consequence of infliximab and review the literature on pericardial complications stemming from this drug class.Methods. For the literature review, search terms using versions of antitumor necrosis factor alpha AND pericardial effusion OR pericarditis OR pleuropericarditis OR cardiac tamponade were used.Results. Pericarditis is a rare but serious complication of anti-TNF based therapy, and hemorrhagic fluid is even more rare, with only one additional case reported. It is likely that this complication was secondary to a robust immune response to very high titer anti-infliximab antibodies. Providers should be aware that this complication can occur and that abnormal elevations in procalcitonin may accompany this unusual finding.
No takes yet. Share an insight, caveat, or question.
Lather et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: